Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.
Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M; Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT).
Passweg JR, et al. Among authors: cahn jy.
Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121. Epub 2015 Jun 1.
Bone Marrow Transplant. 2015.
PMID: 26030052
Clinical Trial.